Author

Todd Henninger

Observed names: T Henninger, T. Henninger

Institution: Johnson & Johnson (United States)

Observed institutions: The University of Sydney, Royal Adelaide Hospital, Johnson & Johnson (United States), The University of Texas MD Anderson Cancer Center, Lund University, Concord Repatriation General Hospital, Skåne University Hospital, Janssen Research & Development (United States), University of Bologna

OpenAlex ID: A5026620586

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

2022 · Michael L. Wang, Wojciech Jurczak, et al. · New England Journal of Medicine · 227

Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

2018 · S Rule, W Jurczak, et al. · Leukemia · 101

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab

2025 · Shaji Kumar, María-Victoria Mateos, et al. · New England Journal of Medicine · 48

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

2023 · Loretta J. Nastoupil, Georg Hess, et al. · Blood Advances · 28

Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).

2022 · Michael Wang, Wojciech Jurczak, et al. · Journal of Clinical Oncology · 12

Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years

2025 · María-Victoria Mateos, Hila Magen, et al. · Blood · 9

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

2025 · Saad Usmani, Shaji Kumar, et al. · Blood · 6

Ibrutinib Vs Temsirolimus: Three‐year Follow‐up of Patients With Previously Treated Mantle Cell Lymphoma From the Phase 3, International, Randomized, Open‐label Ray Study

2017 · S. Rule, W. Jurczak, et al. · Hematological Oncology · 4

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status

2025 · Ciara L. Freeman, Srimathi Srinivasan, et al. · Blood · 2

Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma

2025 · Per Olsson Gisleskog, Belén Valenzuela, et al. · CPT Pharmacometrics & Systems Pharmacology · 1

Ibrutinib Plus Br or R‐chop in Previously Treated Patients With Follicular or Marginal Zone Lymphoma: the Phase 3 Selene Study

2023 · L. J. Nastoupil, G. Hess, et al. · Hematological Oncology · 1

RP2R dose selection of Tal + Tec for the treatment of EMD patients in the RedirecTT-1 study.

2026 · Nicholas Au, Dongfen Yuan, et al. · Journal of Clinical Oncology

S209: Primary Results From the Phase 3 Shine Study of Ibrutinib in Combination With Bendamustine-rituximab (br) and R Maintenance as a First-line Treatment for Older Patients With Mantle-cell Lymphoma

2022 · M. L. Wang, W. Jurczak, et al. · HemaSphere

Works count: 13

Citation count: 439

H-index: 6

I10-index: 5